^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

anti- MESO CAR-T cells

i
Other names: anti- MESO CAR-T cells, autologous genetically modified anti- MESO CAR transduced T cells
Associations
Company:
Hrain Biotech
Drug class:
Mesothelin-targeted CAR-T immunotherapy
Associations
3years
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer (clinicaltrials.gov)
P1, N=10, Recruiting, Shanghai 6th People's Hospital | Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2021 --> Jan 2023
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
MSLN (Mesothelin)
|
MSLN expression • MSLN positive
|
fludarabine IV • anti- MESO CAR-T cells • cyclophosphamide intravenous